Has Crizotinib been launched in China
Crizotinib, as an ALK/ROS1 inhibitor, has been launched in China. However, attention should be paid to the approval status and medication safety issues for different indications. Patients should purchase it through formal channels and strictly follow medical advice.
1. Domestic listing status
(1) Approval status: crizotinib has been approved for marketing by the China National Medical Products Administration and is suitable for the treatment of ALK positive non-small cell lung cancer.
(2) Scope of indications: Currently, the approved indication in China is first-line treatment for ALK positive advanced NSCLC, while the indication for ROS1 positive NSCLC has not been officially approved.
2 Medication precautions
(1) Prescription requirement: Purchase from a regular medical institution with a prescription from a specialist physician, and self adjustment of dosage is prohibited.
(2) Adverse reactions: Common visual impairments, gastrointestinal reactions, etc. Regular monitoring of liver function and electrocardiogram is required during medication.
3 Suggestions for purchasing channels
(1) Regular channels: It is recommended to purchase through hospital pharmacies or chain pharmacies, and keep the complete drug packaging and invoice.
(2) Anti counterfeiting identification: Pay attention to checking the drug approval number (starting with the Chinese medicine standard letter H), production batch number, and expiration date information.
- Previous:Crizotinib is launched in China
- Next:How effective is Upadacitinib
Disclaimer：《Has Crizotinib been launched in China》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！